Mirae Asset Global Investments
MCRB icon

Mirae Asset Global Investments’s Seres Therapeutics MCRB Stock Holding History

Mirae Asset Global Investments’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,505
Closed -$278K – 2116
2024
Q1 		$278K Buy
+2,505
New +$54K ﹤0.01% 2140
2023
Q4 		– Sell
-4,161
Closed -$198K – 2574
2023
Q3 		$198K Buy
4,161
+189
+5% +$14.4K ﹤0.01% 2303
2023
Q2 		$378K Buy
3,972
+860
+28% +$93.6K ﹤0.01% 2076
2023
Q1 		$353K Buy
3,112
+449
+17% +$48.6K ﹤0.01% 2087
2022
Q4 		$298K Buy
2,663
+3
+0.1% +$402 ﹤0.01% 2159
2022
Q3 		$342K Buy
+2,660
New +$272K ﹤0.01% 2100

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirae Asset Global Investments's MCRB Position: Q2 2024 in Review

Mirae Asset Global Investments sold out of Seres Therapeutics (MCRB) in Q2 2024, closing a stake of 2,505 shares — an estimated $278K sold.

Mirae Asset Global Investments first reported a position in MCRB in Q3 2022 and held it in 6 quarters. The position peaked at $378K in Q2 2023. 93 funds tracked by Wall St. Rank hold MCRB as of Q2 2024.

  • Mirae Asset Global Investments reported no remaining Seres Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,505 Seres Therapeutics shares in Q2 2024, an estimated $278K.
  • Mirae Asset Global Investments first reported a position in Seres Therapeutics in Q3 2022 and held it in 6 quarters.
  • Mirae Asset Global Investments's Seres Therapeutics position peaked at $378K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2024.

Based on Mirae Asset Global Investments's 13F filing for Q2 2024, filed 30 Jul 2024.